论文部分内容阅读
Adenosine A2A receptor(A2AR)has been the novel non-dopaminergic therapeutic agent for the management of Parkinsons disease(PD).In rodent and primate parkinsonian models,blockade of A2AR can bring symptomatic relief from parkinsonian motor deficits without L-dopa-related motor side effects,such as dyskinesia and "wearing off".